EUCOPE adds five new members to its association
As the EU trade body for small to mid-sized companies that support, invest and produce the innovative medicines and therapies of the future, EUCOPE is happy to welcome five new members to its organisation.
AOP Health, Enterome, Flatiron Health, Novo Nordisk and TETEC all became members of EUCOPE at the end of February 2022.
AOP Health is the European pioneer for integrated therapies for rare diseases and critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries, and representative offices throughout Europe and the Middle East, as well as through partners worldwide.
“We are now a proud member of EUCOPE to join forces to transforming the patient’s experience with our passion, know-how and dedication,” said Andreas Steiner, Group CEO. Adding into the mix, Johanna Grames, Corporate Affairs Manager noted “my personal ambition is to build the corporate affairs activities in our company. I am so glad we joined EUCOPE – a hands-on, well informed and actively engaged European confederation who supports our vision to bring innovative therapies to patients.”
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
“We welcome the opportunity to join EUCOPE and its unique support and network. We strongly believe it will help Enterome to access a more precise view on both regulatory and market environments and help us to achieve more efficiently the development of our innovative treatments for the benefit of patients suffering from diseases with strong unmet medical need” said Pierre Belichard, CEO of Enterome.
Flatiron Health is a health tech company dedicated to improving cancer treatment and advancing research. As the pioneer in real-world evidence for oncology, they provide technology and services to support patient care and make every patient story count. They partner with hundreds of cancer centers, 20+ top global developers of oncology therapeutics, and researchers and regulators around the world.
“Flatiron Health is proud to join EUCOPE and looks forward to working together to advance the use of Real-World Evidence in regulatory decision-making,” said Nathan Hubbard, SVP & GM of Flatiron International. “In working with our EUCOPE partners, we hope to help establish an optimal regulatory environment to enable us to deliver on the promise of Real-World Data and Real-World Evidence and to help improve patients’ lives.”
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Novo’s purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. They do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases they treat.
Founded in 2000, TETEC is led by specialists drawn from a wide range of disciplines who bring with them in-depth knowledge of cellular and molecular biological science, coupled with pharmacological expertise. A subsidiary of Aesculap AG, we guarantee you an outstanding distribution network and work actively to share our knowledge with you through professional user training and support.
“TETEC AG as tissue engineering company in the field of ATMPs is very happy to join EUCOPE to be able to shape and build the political landscape and network towards highly innovative cell based therapies together with other renowned experts in the field”, said Detlef Schumann, CEO TETEC AG
AOP Health, Enterome, Flatiron Health, Novo Nordisk and TETEC will join a trusted network that represents more than 1,300 research-oriented organisations, many of which develop therapeutic solutions for rare diseases as well as cell and gene therapies, to continue to provide innovative patient-centric solutions throughout Europe. We look forward to working with all of our members as we continue to reinforce Europe as a centre for pharmaceutical innovation.